The antibody-drug conjugate trastuzumab deruxtecan continues to show impressive progression-free and overall survival gains in previously treated unresectable and/or metastatic HER2+ breast cancer.
The risk is higher when immunotherapy comes within 3 months of cranial radiotherapy. The study was published as a preprint and has not yet been peer reviewed.
United States health officials are investigating amid measles and respiratory syncytial virus (RSV) outbreaks combined to force pediatric units into critical status.